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Background:  The aim of this study was to evaluate the feasibility, safety and performance of a transcatheter adjustable mitral annuloplasty 
system in patients with functional mitral regurgitation (FMR) in a multicentre study. The Cardioband system (Valtech Cardio, Or Yehuda, 
Israel) enables percutaneous implantation of an adjustable “surgical-like” mitral annuloplasty ring using a transseptal approach.
methods:  Between February 2013 and September 2014, 29 high-risk patients with significant FMR were enrolled at 5 sites in Europe. 
After a Heart Team evaluation all patients were screened by echocardiography and cardiac CT to assess feasibility. Echocardiographic) 
data were analysed by an independent core-lab.
results:  Twenty-four patients were male (83%). Mean age was 72±7 years, mean Log-EuroScore 19±10% and median STS score 7% 
(1.8%-33.8%). 97% of patients were in NYHA class III-IV at baseline. Mean EF was 35±11% (15%-59%). Device implantation was feasible 
in all patients (100%). Acute procedural success (device successfully implanted with acute reduction of MR <2+) was achieved in 89% of 
the patients (26/29). After the adjustment of the device, a 20% reduction of the septo-lateral diameter was observed (from 36±3.5 mm to 
29±5 mm; p=0.01). Thirty-day mortality was 6.8% (Two deaths adjudicated unrelated to the device). At 6 months 90% of patients were in 
NYHA class I-II with significant improvement in quality of life (MLHFQ from 35 to 23; p<0.05). 91% of patients had MR≤2+.
conclusion:  These results suggest that: transseptal direct annuloplasty with an adjustable “surgical-like” ring is feasible, with a good 
safety (safety performance similar to other transcatheter mitral procedures). Effective reduction in MR severity is observed in most patients 
related to a significant septo-lateral dimension reduction. MR reduction is stable at 6 months, with significant clinical benefit.
